BALTIMORE--(BUSINESS WIRE)--Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced Thomas H. Aasen has joined its Board of Directors and will serve on its Audit Committee. Mr. Aasen is a financial executive with over thirty years of professional experience, including financial management positions in four publicly held life science companies.
